Published in

American Association for Cancer Research, Cancer Discovery, 2023

DOI: 10.1158/2159-8290.cd-22-1350

Links

Tools

Export citation

Search in Google Scholar

SUV39H1 Ablation Enhances Long-Term CAR-T Function in Solid Tumors

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Abstract Failure of adoptive T cell therapies in cancer patients is linked to limited T cell expansion and persistence, even in memory-prone 41BB-(BBz)-based chimeric antigen receptor (CAR) T cells. We show here that BBz-CAR T cell stem/memory differentiation and persistence can be enhanced through epigenetic manipulation of the histone 3 lysine 9 tri-methylation (H3K9me3) pathway. Inactivation of the H3K9 tri-methyltransferase SUV39H1 enhances BBz-CAR T cell long-term persistence, protecting mice against tumor relapses and rechallenges in lung and disseminated solid tumor models up to several months after CAR T cell infusion. Single-cell transcriptomic (scRNAseq) and chromatin opening (scATACseq) analyses of tumor infiltrating CAR T cells show early reprogramming into self-renewing, stem-like populations with decreased expression of dysfunction genes in all T cell subpopulations. Therefore, epigenetic manipulation of H3K9 methylation by SUV39H1 optimizes long-term functional persistence of BBz-CAR T cells, limiting relapses and providing protection against tumor rechallenges.